Full-Time

Junior Product Specialist

Posted on 5/30/2026

Deadline 6/14/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

Dubai - United Arab Emirates

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Marketing
Requirements
  • Minimum Bachelor's Degree.
  • Entry level 1 no previous experience required. Fresh graduates with strong potential and learning agility will be considered.
  • Willingness to learn, receive feedback, and continuously develop capabilities.
  • Professional proficiency in written and spoken English.
Responsibilities
  • Supports the promotion of assigned products within approved indications and Company guidelines.
  • Conducts face-to-face and virtual calls with healthcare professionals, using approved promotional materials.
  • Delivers core product messages accurately and compliantly, with coaching from line management.
  • Builds professional relationships with target HCPs over time, focusing on trust and credibility.
  • Supports achievement of territory objectives through disciplined execution of call plans.
  • Maintains accurate and timely CRM reporting in line with Company policies.
  • Applies customer segmentation guidance provided by the Company to ensure appropriate call frequency and channel mix.
  • Keeps customer information updated to support effective planning and follow-up.
  • Develops solid understanding of disease areas, assigned products, and key competitors.
  • Stays up to date with product information and clinical data provided through internal training.
  • Actively participates in training programs, coaching sessions, and field accompaniment.
  • Works collaboratively with Sales Managers, Marketing team, Medical team, and other internal stakeholders.
  • Supports the execution of brand initiatives and local promotional activities.
  • Assists in the organization of educational meetings, symposia, and congresses when required.
  • Fully complies with local laws, HCBI guidelines, FCPA, and the Policy on Business Conduct.
  • Reports Adverse Events and product quality complaints in line with J&J Pharmacovigilance requirements.
  • Demonstrates high standards of ethics, transparency, and professionalism in all interactions

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • CARVYKTI, DARZALEX, and RYBREVANT drive oncology growth despite STELARA erosion.
  • Abu Dhabi’s intelligent OR network accelerates surgical AI data generation and validation.
  • Atraverse and New Jersey Innovation Hub strengthen J&J’s cardiac access and startup sourcing.

What critics are saying

  • STELARA biosimilar erosion keeps crushing immunology revenue and pressures 2026 guidance.
  • Intuitive Surgical and Boston Scientific can outbundle J&J’s open surgery software stack.
  • Rapid MedTech innovation cycles make Shockwave and VARIPULSE vulnerable to faster rival iteration.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech across oncology, immunology, and surgery.
  • Polyphonic links AWS and NVIDIA into an open surgical intelligence ecosystem.
  • Shockwave and VARIPULSE give J&J leading platforms in coronary and electrophysiology procedures.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Johnson & Johnson who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-10%
Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.